NCT06673927已完成1 期
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics of YZJ-1139 in Healthy Participants
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 104
- 试验地点
- 1
- 主要终点
- Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
研究概览
简要总结
Primary Objective：
- To evaluate the tolerability, safety of single and multiple doses of YZJ-1139 in healthy participants
- To evaluate the pharmacokinetic of single and multiple doses of YZJ-1139 in healthy participants
Secondary objectives:
To explore the safe tolerated dose of YZJ-1139, provide data support for the design of phase II dosing regimen
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Healthy subjects, with the proportion of a single gender in each group not less than 1/3;
- •Aged between 18 and 45 years (inclusive of 18 and 45 years);
- •The body mass index (BMI) ranges from 19 to 24 (inclusive of 19 and 24), where BMI = weight (kg) / height squared (m²). At the time of entering the study, the weight of female volunteers must be no less than 50 kg, and that of male volunteers must be no less than 55 kg;
- •Those who pass comprehensive physical examinations (vital signs, height, weight, and chest and abdominal examinations, etc.) and laboratory tests (blood routine, blood biochemistry, urine routine, electrocardiogram, infectious disease screening, etc.), and have no abnormalities or only minor abnormalities without clinical significance in 12-lead electrocardiogram, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, and kidneys), anteroposterior and lateral chest radiographs, etc.;
- •Volunteers who can comprehend the procedures and methods of this study, are willing to strictly adhere to the clinical trial protocol to complete the trial, and sign the informed consent form.
排除标准
- •After researchers determine that the subject has a disease that affects drug absorption, distribution, metabolism, and excretion or may reduce compliance (cardiovascular, liver, kidney, gastrointestinal, immune, hematological, endocrine, metabolic, cancer, psychiatric and neurological conditions);
- •A history of specific allergic reactions (such as asthma, eczema, allergic dermatitis); known allergies to the trial drug and its excipient components; a history of drug allergies;
- •A history of obstructive sleep apnea or chronic obstructive pulmonary disease;
- •A history of severe unconscious hypoglycemia;
- •A history of stroke, chronic epilepsy, or neurological disorders;
- •A history of diminished memory or abnormal behavior;
- •A history of drug dependence within the past 2 years (smoking excluded), seizure disorders, syncope history;
- •A clinically significant illness within the past month before enrollment, especially severe infections, trauma, or major surgery;
- •The use of any prescription drugs or herbal medicines within the past month before enrollment, and non-prescription drugs or food supplements within the past 2 weeks;
- •Regular use of sedatives, sleeping pills, or other addictive drugs, and positive urine drug screening;
- •had donated blood within the 3 months prior to the study, or had severe blood loss equivalent to at least 500 mL of blood loss;
- •Hepatitis B surface antigen positive, hepatitis C antibody positive, HIV antibody positive, syphilis antibody positive;
- •Patients who took CYP3A enzyme inhibitors (itraconazole, erythromycin, boprevir, etc.), CYP3A enzyme inducers (rifampicin, carbamazepine) and/or CNS inhibitors (benzodiazepines, opioids, tricyclic antidepressants, etc.) 2 weeks before inclusion;
- •Have a history of alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or about 100 ml of wine) and test positive for alcohol;
- •Smokers who smoked more than 5 or equivalent cigarettes per day in the 3 months before the test and those who tested positive for nicotine should not give up smoking during the test;
- •Drinking excessive tea and coffee drinks (more than 8 cups) per day;
- •Drinking alcohol, eating food and drink rich in xanthine or caffeine (including chocolate, tea, coffee, cola, etc.) or eating grapefruit, limes, etc., or food and drink prepared from them in the 3 days prior to inclusion;
- •Participated in any clinical drug research or clinical trial of medical device within 3 months prior to screening;
- •Pregnant and lactating women within 6 months from the subject's signature to the last administration of the study drug; Fertile women who do not use effective non-hormonal contraception (Iuds, barrier contraception with spermicide or surgical sterilization, etc.) or are unwilling to continue using these methods; Fertile men are reluctant to use physical methods of contraception; Women who were menstruating during the trial (see annex 3 for details);
- •There are any subjects that the investigator considers unsuitable for participation in this study.
研究组 & 干预措施
YZJ-1139 Single-dose Group
Experimental
Subjects will be randomized into two groups： the experimental group will receive YZJ-1139; the control group will receive placebo.
干预措施: YZJ-1139 (Drug)
YZJ-1139 multiple-dose Group
Experimental
Subjects will be randomized into two groups；the experimental group will receive YZJ-1139; the control group will receive placebo once a day, 7 days.
干预措施: YZJ-1139 (Drug)
YZJ-1139 multiple-dose Group
Experimental
Subjects will be randomized into two groups；the experimental group will receive YZJ-1139; the control group will receive placebo once a day, 7 days.
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
时间窗: From Day 1 to Day 3 post single dose；From Day 1 to Day 14 post multiple dose；
次要结局
- CL/F of YZJ-1139(From Day 1 to Day 2 post single dose；From Day 1 to Day 8 post multiple dose)
- AUCinf of YZJ-1139(From Day 1 to Day 2 post single dose；From Day 1 to Day 8 post multiple dose)
- AUC0-τ of YZJ-1139(From Day 1 to Day 8 post multiple dose)
- Tmax of YZJ-1139(From Day 1 to Day 2 post single dose；From Day 1 to Day 8 post multiple dose)
- Css,avg of YZJ-1139(From Day 1 to Day 8 post multiple dose)
- Css,min of YZJ-1139(From Day 1 to Day 8 post multiple dose)
- Rac of YZJ-1139(From Day 1 to Day 8 post multiple dose)
- AUClast of YZJ-1139(From Day 1 to Day 2 post single dose；From Day 1 to Day 8 post multiple dose)
- Cmax of YZJ-1139(From Day 1 to Day 2 post single dose；From Day 1 to Day 8 post multiple dose)
- t1/2 of YZJ-1139(From Day 1 to Day 2 post single dose；From Day 1 to Day 8 post multiple dose)
- Vz/F of YZJ-1139(From Day 1 to Day 2 post single dose；From Day 1 to Day 8 post multiple dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese ParticipantsHealthy VolunteersNCT05405543Bristol-Myers Squibb36
已完成
1 期
99mTc-rhAnnexin V-128: a First In Man Study in Healthy VolunteersHealthy Adult VolunteersNCT02182609Advanced Accelerator Applications14
尚未招募
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid TumorsAdvanced Malignant Solid TumorNCT05911984Mabwell (Shanghai) Bioscience Co., Ltd.27
Unknown
1 期
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid TumorsLung CancerLymphomaNCT02836834Shanghai Junshi Bioscience Co., Ltd.33
已完成
1 期
A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid TumorsSolid TumorNCT06209385Shanghai Haiyan Pharmaceutical Technology Co., Ltd.14